Fusion Pharmaceuticals
cohort in cold hot dosing regimen showed promising results that supported dose in june fusion reported data from the first cold hot dosing cohort at no limited to transient grade or less thrombocytopenia patients showed stable disease ovarian patient received cycles of therapy dose escalated to | Fusion Pharmaceuticals
Company
Deck Type
Sector
Industry
Deck date
January 2024
Slide
18 of 26
Related slides by other companies
argenx SE
Results
June 2023
for multifocal motor neuropathy advancing phase study to cohort a | argenx SE
Ocuphire Pharma
Investor Presentation
May 2023
profile overview well tolerated oral dose up to day twice daily dosing progression of diabetic minimal ocular side effects ire cine | Ocuphire Pharma
Aeglea BioTherapeutics
Investor Presentation
October 2023
spy phase clinical trial design | Aeglea BioTherapeutics
Erasca
Investor Presentation
January 2024
dose cohorts | Erasca
Other recent decks by Fusion Pharmaceuticals
See all presentations (4 decks)
Investor Presentation
November 2023
Investor Presentation
August 2023
IPO
June 2020
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io